Check for updates

OPINION ARTICLE

REVISED How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved]

Paulo Luz , David Dias, Ana Fortuna, Luis Bretes, Beatriz Gosalbez

Medical Oncology, Centro Hospitalar Universitário do Algarve, Faro, Portugal

v2 First published: 16 Sep 2019, 8:1649
<https://doi.org/10.12688/f1000research.20509.1>
 Latest published: 04 May 2020, 8:1649
<https://doi.org/10.12688/f1000research.20509.2>

Abstract

Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes.

How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBC

Keywords

triple negative, breast cancer, neoadjuvant chemotherapy

This article is included in the **Oncology** gateway.

Open Peer Review**Approval Status**

	1	2
version 2 (revision) 04 May 2020		 view
version 1 16 Sep 2019	 view	

1. **Brian D. Lehmann**, Vanderbilt University Medical Center, Nashville, USA

2. **Bruna Cerbelli**, Sapienza University, Latina, Italy

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Paulo Luz (p_luz@msn.com)

Author roles: **Luz P:** Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Dias D:** Writing – Original Draft Preparation; **Fortuna A:** Resources; **Bretes L:** Supervision, Validation; **Gosalbez B:** Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Luz P *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Luz P, Dias D, Fortuna A *et al.* **How shall we treat locally advanced triple negative breast cancer? [version 2; peer review: 2 approved]** F1000Research 2020, 8:1649 <https://doi.org/10.12688/f1000research.20509.2>

First published: 16 Sep 2019, 8:1649 <https://doi.org/10.12688/f1000research.20509.1>

REVISED Amendments from Version 1

New evidence about immunotherapy in early TNBC is available. We incorporate that information in this new version of the article. We have also been able to incorporate changes to reflect most of the suggestions provided by the reviewer i.e. brief discussion of immune checkpoint inhibitors in a neoadjuvant setting.

Any further responses from the reviewers can be found at the end of the article

Triple negative breast cancer (TNBC) is immunohistochemically defined as the lack of expression of estrogen, progesterone receptor and human epidermal growth factor receptor 2 (HER-2). It accounts for 15–20% of breast cancer cases and is characterized as a molecular heterogeneous disease that usually presents an aggressive clinical behavior and higher prevalence in younger women¹. Once TNBC has metastasized, it has the worst prognosis and the shortest OS of all breast cancer subtypes. On the other hand, TNBCs are highly chemo-sensitive and have been shown to respond very well to neoadjuvant chemotherapy (NACT)^{1–3}.

The main goal of NACT strategies are not only to decrease the need for radical mastectomy but also to obtain an important predictive marker of favorable prognosis - the pathological complete response (pCR) - which is defined as the absence of invasive tumor cells (ypT0/is, ypN0/is). A correlation was observed between the pCR and the overall survival (OS) and disease free survival (DFS) outcomes in all subtypes of breast cancer, especially in aggressive ones such as HER2 positive and TNBC². The pCR achieved by NACT represents to date the ideal endpoint in translational investigation of biomarkers and pharmacological treatments. Patients who do not have pCR after NACT with the combination of taxane and anthracycline have 20 to 30% risk of relapse^{2,3}.

How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution. A metaanalysis that enrolled nine randomized clinical trials (RCT) with 2109 patients showed that platinum-based NACT compared to platinum-free NACT significantly increased pCR rate from 37.0% to 52.1%⁴. However, only two RCTs (GeparSixto trial and CALGB 40603) reported survival outcomes: no significant difference in event free survival (EFS) and OS was observed in the combined analysis^{5,6}. In the CALGB study⁶ adding carboplatin did not significantly impact survival. The absolute benefit in 3-year event-free survival of adding carboplatin was 4.9% and the OS differences were also not significant, with 81.9% OS in the carboplatin group versus 84.6% without carboplatin. These results conflict with those in the GeparSixto trial⁵. In the TNBC subgroup, carboplatin resulted in a significantly improved pCR rate over control (53% vs 37%; $P = 0.005$). This translated into an absolute benefit in 3-year event EFS for the addition of carboplatin over control of 9.7% (85.8% vs 76.1%, respectively). What reasons can explain this discrepancy? There are several differences between these two studies worth

noting. GeparSixto had more-favorable baseline characteristics, as 56% of patients were cN0, compared with 42% in CALGB, 76% of patients had tumors of high grade in CALGB, while 65% of tumors were high grade in GeparSixto, albeit in both TNBC and HER2. Long term survival analysis is needed. Additionally, a larger proportion were cT1 in GeparSixto (26% vs 11%). In CALGB 40603, the backbone therapy also included cyclophosphamide, which can also cause DNA damage like platinum agents, potentially making the treatment effect similar in the control and experimental arms^{5,6}. Notably, BRCA-mutated patients experienced overall higher pCR rates, although no benefit was observed with the incorporation of platinum agents⁴.

Current controversy in this field also includes the benefit of additional therapy after surgery. Given the still significantly high rates of residual disease after neoadjuvant therapy in TNBC, which portends inferior DFS, another approach to improving outcomes in this population is to add additional adjuvant therapy after surgery. The great majority of the studies focus on capecitabine, an active drug in metastatic TNBC. In the CREATE X trial (Capecitabine for Residual Cancer as Adjuvant Therapy)⁷ patients who have not achieved pathologic complete response after undergoing neoadjuvant therapy were randomized to receive standard treatment either with capecitabine or without (control). Among patients with triple negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group, and the overall survival rate was 78.8% versus 70.3%⁷. At the San Antonio Breast Cancer Symposium 2018, the results of the phase III trial conducted by the Spanish group and the Central and South American group were presented, where treating patients with early-stage TNBC with capecitabine after surgery and standard chemotherapy did not significantly improve disease-free or overall survival compared with observation group⁸. One possible explanation for the discrepancy between the results of the CREATE-X trial and this trial may be the different prognostic features between the populations. The risk of relapse of the population was much lower than in the CREATE-X trial. So, capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place.

An important question remains, should standard of care with NACT on TNBC rely on platinum-based treatments with the intent of achieving higher pCR rates and a probable benefit in OS or should it continue with taxane and anthracycline based combinations and consider the use capecitabine when pCR is not feasible?

According to the authors' perspectives, the impact of platinum on pCR and OS cannot simply be ignored. This option must be considered after balancing the potential benefits on disease outcomes versus increased toxicity. Special attention must be placed in older and frail patients that are still capable and willing to undergo NACT. In this subgroup of patients, taxane and anthracycline combination remains a valid first choice treatment and adjuvant capecitabine should be considered when residual tumor is still present. In young high risk patients who underwent platinum-based NACT and didn't achieve pCR, adjuvant

capecitabine should be discussed even we don't have any RCT to support this idea.

Chemotherapy remains the backbone of TNBC, but research and development of new modalities of treatment continues. Recent and promising results were available in the metastatic setting with immunotherapy and in the near future that can play a role in early stage. KEYNOTE-522⁹ included 602 women with early TNBC and randomly assigned them to receive neoadjuvant therapy with four cycles of carboplatin/paclitaxel, followed by four cycles of anthracycline with or without pembrolizumab. After surgery, patients received nine cycles of adjuvant pembrolizumab or placebo. Both PD-L1-positive and PD-L1-negative patients achieved pCR. In PD-L1-positive patients, pCR were 68.9% vs 54.9%, respectively. In PD-L1-negative patients, pCR rates were 45.3% vs 30.3%, respectively. On the other hand, NeoTRIP¹⁰ randomly assigned 280 women with early or locally advanced TNBC to receive neoadjuvant therapy with either atezolizumab plus carboplatin/nab-paclitaxel or placebo plus the same chemotherapy. All patients underwent surgery and then received four further cycles of anthracycline-based chemotherapy. pCR rates were not significantly different between the two study arms: 43.5% with atezolizumab vs 40.8% with chemotherapy alone. A multivariate analysis showed that the only

variable associated with pCR rate was PD-L1-positive status ($P < .0001$).

One of the possible explanations for the difference seen in these two trials may at least in part be related to the chemotherapy backbone. In the KEYNOTE-522 study, patients received anthracyclines in the neoadjuvant phase, whereas this was given after surgery without atezolizumab in NeoTRIP. Moreover, there appeared to be patients with higher-risk disease in NeoTRIP compared with KEYNOTE-522: the first trial included patients with N3 disease (15% of patients), while the KEYNOTE-522 study excluded and more patients had stage IIIA and IIIB disease (49% vs. 25%).

More studies are needed to identify which patients will benefit and whether one checkpoint inhibitor is better than another. We hope that some of these drugs may soon have a role in the neoadjuvant setting. Right now, we know neoadjuvant treatment allows us to re-write the story right at the start and we just cannot miss that opportunity.

Data availability

Underlying data

No data are associated with this study.

References

1. Harbeck N, Gnant M: **Breast cancer**. *Lancet*. 2017; **389**(10074): 1134–1150.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Cortazar P, Zhang L, Untch M, *et al.*: **Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis**. *Lancet*. 2014; **384**(9938): 164–172.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. von Minckwitz G, Untch M, Blohmer JU, *et al.*: **Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes**. *J Clin Oncol*. 2012; **30**(15): 1796–1804.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Poggio F, Bruzzone M, Ceppi M, *et al.*: **Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis**. *Ann Oncol*. 2018; **29**(7): 1497–1508.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Untch M, Schneeweiss A, Salat C, *et al.*: **163PDLong-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto)**. *Ann Oncol*. 2017; **28**(suppl_5).
[Reference Source](#)
6. Sikov W, Berry D, Perou C, *et al.*: **Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)**. *Cancer Res*. 2016; **76**(4 Supplement): S2-05-S2-05.
[Publisher Full Text](#)
7. Masuda N, Lee SJ, Ohtani S, *et al.*: **Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy**. *N Engl J Med*. 2017; **376**(22): 2147–2159.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Martín M, Barrios CH, Torrecillas L, *et al.*: **Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer**. *Cancer Res*. 2019; **79**(4 Supplement): GS2-04 LP-GS2-04.
[Publisher Full Text](#)
9. Schmid P, Cortes J, Pusztai L, *et al.*: **Pembrolizumab for Early Triple-Negative Breast Cancer**. *N Engl J Med*. 2020; **382**(9): 810–821.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Gianni L, Huang C, Egle D, *et al.*: **Pathologic complete response to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study**. 2019 San Antonio Breast Cancer Symposium. Abstract GS3-04. Presented December 12, 2019.
[Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 06 August 2020

<https://doi.org/10.5256/f1000research.26216.r67500>

© 2020 Cerbelli B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Bruna Cerbelli

Medico-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Rome, Italy

- The authors provide their opinion about the old and novel therapeutic strategy in non metastatic TNBC.
- The trial is well analysed and commented; however, the manuscript requires some improvement of English.
- In the context of novel option, the authors should discuss the negative results of neoadjuvant GEPAR nuevo study, presented at ASCO 2018 and the role of window study.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Partly

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 21 January 2020

<https://doi.org/10.5256/f1000research.22542.r58166>

© 2020 Lehmann B. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Brian D. Lehmann

¹ Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

² Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

In this article the authors provide perspective on the use of platinum compounds in the treatment of early stage triple-negative breast cancer. The authors provide opinions on a recently published meta-analysis of nine randomized clinical trials (RCT) treated with platinum-based neoadjuvant chemotherapy.

Specific comments:

1. Please finish the sentence, "Notably, BRCA-mutated patients experienced overall higher pCR rates, although no benefit was observed with the." The sentence and idea trying to be presented is incomplete.
2. The authors state, "What reasons can explain this discrepancy? There are several differences between these two-studies worth noting. GeparSixto had more-favorable baseline characteristics, as 26% of patients were cN0, compared with 42% in CALGB 40603." This statement does not appear to be accurate. How is 26% of patients with cN0 in GeparSixto more favorable than 42% of patients with cN0 in CALGB? Please revise and double check the numbers. 42% is correct for CALGB as the patient population was limited to TNBC. GeparSixto included both TNBC and HER2 positive and at least in the combined population cN0 was 50%. Not sure what the value is when restricted to TNBC. The authors should consider comparing tumor grade, as higher grades are associated with better chemotherapy response. In CALGB 76% of patients had tumors of high grade, while 65% of tumors were high grade in GeparSixto, albeit in both TNBC and HER2.
3. The statement, "Recently, at the San Antonio Breast Cancer Symposium 2018...)" is not so recent anymore. Consider removing "recent" or replacing with newer published data.
4. The authors propose the very relevant question, "An important question remains, should standard of care with NACT on TNBC rely on platinum-based treatments with the intent of achieving higher pCR rates and a probable benefit in OS or should it continue with taxane and anthracyclin based combinations and consider the use capecitabine when pCR is not feasible?" While the authors mention the data cannot be ignored, the authors do not mention how the question might finally be resolved. Especially given that there were no EFS or OS benefits from the two studies with published results, how can we justify the substantial toxicities of an additional platinum compound? Perhaps only when we see

additional long-term analysis from the majority of RCTs with platinum compounds could the question be answered.

5. The authors conclude with, "We hope that some of these drugs, like immunotherapy, may soon have a role in the neoadjuvant setting." While this may certainly be true in the metastatic setting, recent results suggest that this may not be the case in the neoadjuvant setting. Please include a discussion of immune checkpoint inhibitors in the neoadjuvant setting. Results from the NeoTRIPaPDL1 trial presented at SABC 2020 (Abstract #GS3-04) concluded that Atezolizumab with neoadjuvant chemotherapy does not improve pathologic complete response rates for patients with triple-negative breast cancer.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Partly

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Triple-negative breast cancer, translational research and genomics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 28 Apr 2020

Paulo Luz

We appreciate the time and effort that you have dedicated to providing your valuable feedback on our manuscript. New evidence about immunotherapy in early TNBC is available (NeoTRIP and KEYNOTE 522). We incorporated that information in this new version of the article.

We have also been able to incorporate changes to reflect most of the suggestions provided by you.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research